BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1285 related articles for article (PubMed ID: 17984104)

  • 1. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.
    Steinman TI
    Nephrol Dial Transplant; 2008 Feb; 23(2):431-3. PubMed ID: 18065782
    [No Abstract]   [Full Text] [Related]  

  • 3. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
    Suwelack B; Kobelt V; Erfmann M; Hausberg M; Gerhardt U; Rahn KH; Hohage H
    Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.
    Siewert-Delle A; Ljungman S; Hartford M; Wikstrand J
    Am J Hypertens; 1995 Feb; 8(2):113-23. PubMed ID: 7755939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients.
    Armentano RL; Graf S; Ramírez AJ; Espinosa JD; Brandani L; Baglivo H; Sánchez R
    Medicina (B Aires); 2001; 61(5 Pt 1):535-40. PubMed ID: 11721319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension in autosomal dominant polycystic kidney disease: observational study in 207 patients with a mean follow-up of 107 months.
    De Almeida EA; Prata MM
    Rev Port Cardiol; 2007 Nov; 26(11):1173-82. PubMed ID: 18297839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Ulusoy S; Ozkan G; Orem C; Kaynar K; Koşucu P; Kiriş A
    Ren Fail; 2010; 32(8):913-7. PubMed ID: 20722556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].
    Erley CM; Berger ED; Heyne N; Klass M; Krämer D; Braun N; Wolf S; Risler T
    Dtsch Med Wochenschr; 1997 Aug; 122(31-32):953-8. PubMed ID: 9280714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
    Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
    Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.
    Erley CM; Klass M; Krämer D; Berger E; Heyne N; Braun N; Wolf S; Risler T
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):504-9. PubMed ID: 8937934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.
    Linz W; Schäfer S; Afkham F; Gerl M; Schmidts HL; Rütten H
    J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):155-61. PubMed ID: 17094052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strict blood-pressure control and progression of renal failure in children.
    ; Wühl E; Trivelli A; Picca S; Litwin M; Peco-Antic A; Zurowska A; Testa S; Jankauskiene A; Emre S; Caldas-Afonso A; Anarat A; Niaudet P; Mir S; Bakkaloglu A; Enke B; Montini G; Wingen AM; Sallay P; Jeck N; Berg U; Caliskan S; Wygoda S; Hohbach-Hohenfellner K; Dusek J; Urasinski T; Arbeiter K; Neuhaus T; Gellermann J; Drozdz D; Fischbach M; Möller K; Wigger M; Peruzzi L; Mehls O; Schaefer F
    N Engl J Med; 2009 Oct; 361(17):1639-50. PubMed ID: 19846849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term renal function in primary hypertension. An epidemiological and pathophysiological study.
    Siewert-Delle A
    Scand J Urol Nephrol Suppl; 1999; 199():1-36. PubMed ID: 10349677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study.
    Pascual JM; Rodilla E; Miralles A; Gonzalez C; Redon J
    J Hypertens; 2006 Nov; 24(11):2277-84. PubMed ID: 17053551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
    Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
    JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.